safety data News
Most Popular safety data Story
Investors fret over Lilly's pipeline, Prasugel data
Barron's concludes that Eli Lilly's anti-clotting drug Prasrugel will probably make it to the market, but recent safety data is likely to prevent it from becoming the kind of blockbuster the drug Read more...
Latest Headlines
- May 21, 2008
- May 9, 2008
- April 23, 2008
- February 27, 2008
- February 11, 2008
- January 24, 2008
- January 17, 2008
- January 10, 2008
- January 8, 2008
- November 21, 2007
- August 28, 2007
- August 10, 2007
- December 19, 2006
- November 5, 2006
- October 1, 2006
- September 12, 2006
- June 14, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
